New Results

A Novel Method of Immunomodulation of Endothelial cells Using Streptococcus Pyogenes and its Lysate

Mark Christopher Arokiaraj, Jarad Wilson
doi: https://doi.org/10.1101/2020.05.13.082180

Abstract

Background Coronary artery diseases and autoimmune disorders are common in clinical practice. In this study, a novel method of immune-modulation to modify the endothelial function was studied to modulate the features of the endothelial cells, and thereby to reduce coronary artery disease and other disorders modulated by endothelium.

Methods HUVEC cells were seeded in the cell culture, and streptococcus pyogenes were added to the cell culture, and the supernatant was studied for the secreted proteins. In the second phase, the bacterial lysate was synthesized, and the lysate was added to cell culture; and the proteins in the supernatant were studied at various time intervals.

Results When streptococcus pyogenes alone was added to culture, E Cadherin, Angiostatin, EpCAM and PDGF-AB were some of the biomarkers elevated significantly. HCC1, IGFBP2 and TIMP were some of the biomarkers which showed a reduction. When the lysate was added, the cell-culture was maintained for a longer time, and it showed the synthesis of immune regulatory cytokines. Heatmap analysis showed a significant number of proteins/cytokines concerning the immune/pathways, and toll-like receptors superfamily were modified. BLC, IL 17, BMP 7, PARC, Contactin2, IL 10 Rb, NAP 2 (CXCL 7), Eotaxin 2 were maximally increased. By principal component analysis, the results observed were significant.

Conclusion There is potential for a novel method of immunomodulation of the endothelial cells, which have pleiotropic functions, using streptococcus pyogenes and its lysates.

Background

Immune-related disorders are common in clinical practice. Though commonly handled disease by the immune system is an infection, most of the other disorders like autoimmune disorders, leukemias, and even non-communicable diseases have an immune basis. A broad-spectrum treatment method to modulate immune disorders would be useful.

Rheumatic heart diseases are common in the general population in the Asian countries with a prevalence of about 7.7 to 51/1000 community based on echocardiography screening in school in India.1 Streptococcus pyogenes infections are associated with sore-throats, and they are also associated with rheumatic heart diseases. Rheumatic fever is associated with migratory joint pains and occasionally pan-carditis. In patients with rheumatic heart diseases, the incidence of coronary artery diseases is low.2-5 This was observed in some studies in India and neighboring countries. Hence, in this study the streptococcus pyogenes infections were used to study the immune modulatory potentials in the endothelial cells.

Streptococcus pyogenes are known to produce a unique enzyme that is useful in cleaving immunoglobulin G in the blood (Ides).6-8 Its usefulness therapeutically has been tested to cleave IgG antibodies.9,10 Streptococcus pyogenes secrete serum optical factor, which shows increased uptake of HDL, and thereby it can reduce atherosclerosis.11,12

In this study, streptococcus pyogenes was used to infect the endothelial cells, and the endothelial response was evaluated. Also, in the later part of the study the streptococcus pyogenes’ lysate was used on the endothelial cells, and the results were evaluated. Microorganisms and their diseases and susceptibility to infections can prevent autoimmune disorders though this phenomenon is not well studied.13 The incidence of autoimmune disorders is common in the migrant populations especially of Asian ethnicity.14,15 This is commonly attributed as the hygiene hypothesis, and the exact mechanism is speculative and not decisively studied.

In our center out of 650 consecutive valve replacement surgeries six cases underwent concomitant coronary artery bypass surgery. Out of these 6 cases a clear etiology of rheumatic heart disease was not established on any of the cases, and the primary etiologies were ischemia MR and degenerative sclerotic calcific aortic valve. The study was performed in search of novel applications of streptococcus pyogenes in regulating immune functions, and its related effects on cardiovascular and its pleiotropic functions.

Methods

Streptococcus pyogenes were obtained from the laboratory (Streptococcus pyogenes Rosenbach – ATCC,19615TM Lancefield Group A). The bacteria were cultured by seeding, and the colonies were inoculated with endothelial cells. Serial observations about the endothelial cells were made at regular intervals by microscopy. The supernatant was collected, and inflammatory markers were studied at serial time intervals.

In the second phase of the study, the streptococcus pyogenes’ lysate was prepared from the same bacteria. The lysate was added to the endothelial cells, and the endothelial cell response was studied at serial intervals -0, 36,138, 336, 672 hours, and control samples were studied. The biomarkers secreted were studied, and the results were achieved.

Statistical Analysis - Data filtration

The biomarkers demonstrating no variation among all the samples (zero variance) were excluded from the data profile analysis since they do not contribute regarding distinguishing samples from each other.

Heatmap

The biomarker values were standardized (centering and scaling) by subtracting the average and then dividing by the standard deviation. The standardized data were plotted in a heatmap with hierarchical clustering by Euclidean distance.

Principal Component analysis

The various expression levels of multiple biomarkers may come from a common underlying factor/mechanism. The principal component analysis (PCA) decompose the data set into different principal components (PCs) sorted by their contribution to total variance/variation in the dataset. These PCs are linear transformations/combinations of standardized biomarker values. By observing the location of a sample on the plot of the first 2 PCs explaining the most variation, we can tell the pattern of samples.

Software

All the analyses were conducted in the R programming language V3.6.0 (R Core Team 2017).

Results

Direct Streptococcus pyogenes’ effects

Tables 1 to 5 summarize the effects of the bacteria on the cell culture of endothelial cells. There is a significant reduction in HCC1, IGFBP2, PDGFAA, and TIMP. Macrophage inhibiting factor and lymphocyte inhibition factors showed a decrease in the levels. There is a marked increase in E Cadherin, Angiostatin, DAN, Ep-CAM, CFG RIIBC, PDGF-AB, gp 130, TPO, Tie 2, and Angiogenin. ICAM-1, IL6, Endoglin, Trail 3, and PRECAM-1 showed an increasing trend.

Streptococcus pyogenes’ Lysate Challenge

The results of the streptococcal lysate challenge on the endothelial cells are summarized in the heat map results (Figure 1). BLC, IL 17, BMP 7, PARC, Contactin2, IL 10 Rb, NAP 2 (CXCL 7), Eotaxin 2 were maximally increased. Other secreted markers that were induced – trappin2, SDF-1a, FGF7, CCL 28, 4-1BB, VCAM 1, VEGF R3, GITR, SIGLEC 5, IL13 R1, CD30, TGF B2 and GP 130. The markers which were unequivocally reduced were MIF, Fas, IL13R2, TIMP2, Follistatin, IGFBP-2, DKK1, TNF R2, Hb EGF. There are 18 biomarkers showing zero variance among all the samples, including BTC, IL-9, IL-29, MCP-4, CD40, DAN, E-Cadherin, b-NGF, EGF R, EG-VEGF, FGF-4, IGF-1, NT-3, SCF, TGFb3, IL-5, BCMA, and E-Selectin. These biomarkers were excluded from the analysis. Details of the principal components and the results are shown in figure 1 and 2 (and supplement file). The results of the principal component analysis are significant.

Figure 1A.
Figure 1A.

Heat map and the classification of the principal components (1-5) for analysis of the biomarkers after streptococcus pyogenes lysate treatment on the endothelial cells.

Figure 1B.
Figure 1B. Legends for Figure 1.
Figure 2:
Figure 2: Shows the variance explained by each principal component

Discussion

The incidence of rheumatic heart disease is showing a decreasing trend, and the incidence of coronary artery disease is rising in the recent days. The incidence in our center and other centers as well show a low association of coronary artery disease with rheumatic valvular heart diseases, irrespective of age and metabolic characteristics.2,3 The incidence of mixed procedure i.e., combined valve surgeries and bypass surgeries, is <5%. And further analysis looking for rheumatic valvular etiology in these combined procedures would be much lesser, even in high volume centers like TUMS.4

Direct streptococcus pyogenes immune response - Decreased biomarkers

Specific biomarkers like HCC1, IGFBP2, PDGF-AA, and TIMP decrease in the levels compared to controls. Hemofiltrate CC is a chemokine, which attracts and acts through CCR1 receptors.16 It is widely secreted by various tissues. Insulin-like growth factor binding protein 2 reduces the risk of diabetes. IGFBP2 is implicated in the regulation of IGF in most tissues.17 Blocking of IGF BP2 results in the reduction of tumor and metastasis.18 Platelet-derived growth factor AA is involved in the migration of smooth muscle cells.19-21 Reduction in the TIMP metallopeptidase inhibitor1 and also has anti-angiogenic activity is associated with a reduction in the adverse clinical events in acute kidney injuries.22 MIF (macrophage migration inhibitory factor) and LIF (leukemia inhibitory factor) levels were reduced. MIF is a widely expressed pleiotropic cytokine, and it is involved in the stimulation of other inflammatory cytokines like TNF alpha, INF gamma, IL6, IL 12, CXCL8 etc.23 LIF is involved in cell differentiation, and maturation and stimulation lead to JAK/STAT and MAPK cascades.24

Increased biomarkers with direct bacterial infection

Increased activity was found in E Cadherin is involved in cell-to-cell interactions, and they have tumor suppressor effects.25 Angiostatin, DAN, is an inhibitor of BMP and TNF. Angiostatin is engaged in the reduction of angiogenesis.26,27 There is a marked increase in EPCAM, which are complex proteins that promote transcription factor-mediated pluripotency reprogramming,28 CFG RIIC and PDGF AB.29 The Platelet-derived growth factor has active angiogenic potential and mitogenesis and acts on various tissues. Angiogenin may maintain blood homeostasis and participates in anti-inflammatory activity and has antibacterial and antiviral properties.30

Streptococcus pyogenes’ lysate effects and Heat map analysis

When the cells were treated with streptococcus pyogenes’ lysate, the levels of BLC -the B lymphocyte chemoattractant protein (CXCL13) was increased.31 Contactin 2 is a neuronal membrane protein, and it acts as an active cell adhesion molecule.32-34 IL 17 is an inflammatory protein, and it was induced after lysate treatment. IL17 induces the production of GCSF and chemokines like CXCL1 and 2.35 IL17 is strongly associated with chronic inflammation associated with autoimmune disorders. PARC (parkin like ubiquitin ligase) is a cytoplasmic anchor protein to p53-associated protein complexes.36-38

CXCL7 is involved in neutrophil chemotaxis, adhesion to the endothelial cells, and trans-endothelial migration of the cells.39-41 Chemokine CXCL 7 is engaged in neutrophil-platelet crosstalk, and also it is actively involved in the growth of renal cell carcinoma.42 IL10 Rb is the receptor for IL10, and it actively participates in inflammatory signaling.43, 44 IL 10 regulates memory T cell development in response to viral infections.45 Eotaxin 2 is an eosinophilic chemoattractant protein, and it acts through CCR3, and it is actively involved in the recruitment of other inflammatory cells also.46 BMP 7 acts on the BMP receptor, which is actively involved in the process of inflammation and atherogenesis. Exogenouos administration of BMP7 improves left ventricular remodeling and function in acute myocardial infarction.47

Trappin 2 is a serine protease inhibitor, and it has anti-inflammatory actions on the mucosal surfaces.48 It also has anti-retrovirus activities on the mucosal surfaces. SDF1 alpha and its chemokine receptor play a significant role in hematopoietic cell mobilization, cancer metastasis, and ischemic injury repair in myocardial infarction tissues.49 FGF 7 (fibroblastic growth factor) has an active role in tissue repair.50 CCL 28 is a mucosa-associated epithelial chemokine, and it is associated with the recruitment of the cells, and it helps in T and B cell accumulation in mucosal surfaces.51 4-1BB (CD137) signalosome promotes T cell proliferation and survival and results in increased T cell effector functions.52,53 VCAM1 is an inflammatory protein involved in cell to cell adhesions, and it also effectively induces angiogenesis.54,55

GITR Glucosteroid induced TNFR related protein is expressed by T cells and its ligands, and it boosts T cell activity. GITR agonistic stimulation is emerging as a promising therapeutic concept.56 SIGLEC 5 is a leucocyte receptor that recognizes sialic acid structures and helps in leucocyte recruitment.57 VEGFR3 is a receptor for vascular endothelial growth factors C and D and it is involved in lymphangiogenesis and to some extent in VEGF A induced angiogenesis as well.58 IL13 overcomes insulin resistance by promoting anti-inflammatory macrophage differentiation in adipose tissue.59 CD30 is expressed on the surfaces of the endothelial cells though it is primarily expressed by lymphoid tissues. They are expressed in non lymphamatous tumours. CD30 signalling is involved in proliferation, differentiation and survival (anti-apoptosis).60 TGF B2 is expressed in the endothelium, and it plays an essential role in angiogenesis.61 GP130 is a glycoprotein that participates in IL6 mediated inflammation and vascular pathologies, and it also has a negative feedback control.62

Reduced biomarkers with lysate

MIF is a widely expressed pleiotropic cytokine, and it is involved in the stimulation of other inflammatory cytokines like TNF alpha, INF gamma, IL6, IL 12, CXCL8 etc.23,63 MIF is elevated in type 1 and 2 diabetes. Fas activation is associated with autoimmune disorders, which can be modulated by downregulation.64 TIMP 2 are matrix metalloproteinases which are involved in inflammation in the cancer cells.65 IGFBP2 are inhibitory and stimulatory to some of the tumours.66 IL13 R2 is involved in mediating inflammation leading to myocarditis. Hence a reduction in these receptors could reduce inflammatory changes.67,68 Dickkopf 1 family proteins are active modulators of Wnt pathways, and mostly their effects are inhibitory.69 TNF R2 has proinflammatory and some anti-inflammatory aspects as well. The stimulatory and inhibitory effects had attracted considerable interest in the treatment of autoimmune diseases and cancer.70 Follistatin is actively involved in activin A-follistatin regulation of cardiac inflammation and fibrosis.71 Heparin-Binding Epidermal Growth Factor-Like Growth Factor Inhibits Cytokine-Induced NF-κB Activation.72 The heat map analysis shows a significant change in more proteins, and thereby it is possible to infer that streptococcus has a role in immune regulation.

The above observations indicate that the immune system undergoes various modifications by the streptococcus pyogenes direct challenge. Certain parameters are increased, and some are decreased. In the long term, the immune memory and its regulation are complex, and it is also subjected to many positive and negative feedback regulations. Also, when the lysate is added, the modulations are seen. Hence, streptococcus pyogenes is associated with changes in the immune system, which can influence potential regulations in the immune homeostasis of the individuals. The negative impact of rheumatic heart diseases can have a positive influence in modifying the immune-related functions and possibly rendering significant protection.

Chaos and decoding

It is indeed difficult to predict the immune response in the future to a certain extent. However, it can be inferred that the endothelial response could be significant and probably chaotic, which determine transcription and gene regulation.73 Chaos does not necessarily lead to dysfunctions, and at times and situations, it could be a natural method of selection to strengthen immune functions. Optical laser chaos signals which are high speed when studied are found to synchronize and it has many features.74, 75 Decoding these chaotic signals in immune system would potentially lead to our better understanding of immune system and modify its treatment which are significant challenges to at present.

Streptococcus vs. viral infections – both together forever

In the recent times coronavirus infections (Covid-19) pandemic is rampant, and the infection selectively affects various countries, and the mortality statistics were varied in different countries. These could be due to varied climatic conditions and the immune response to the viruses. The Southeast Asian countries and the Indian subcontinent are relatively less affected so far, at his time of writing. The streptococcus pyogenes, tropical bacterial infections and other viral are common in these areas, and they could provide cross-immunity to the coronaviral infections.76 Bacteria can synthesize restriction enzymes like nucleases and inhibit viruses.77 It has been shown that bacterial presence can reduce the intensity of viral infections.78 Our study also reflects the immune regulation changes due to streptococcus pyogenes as well as by its lysate.

Hygiene and the Dirt

In the theory of natural selection, the environment or the Nature in various forms could offer protection by its selective mechanisms in various geographic locations.79 These could not necessarily be simple mechanisms but also as chaotic or cross-immunity methods. The commonly available streptococcus bacteria and the common viruses could be the mechanism of choice in the form of selection by unhygienic means.80 Possibly these protective mechanisms are not well studied by the scientific and social communities, and the primary focus is often tertiary care treatment modalities.

Metabolic protection and autoimmunity regulation

The rarity of diabetes and rheumatic heart disease was observed by legendary physicians like Joslin and Steinchron in the early 1920s and 1930’s respectively.81,82 Our study also suggests various metabolic modulators being stimulated and some inhibited. Also, Joseph Barach made similar observations in that period and attributed the views to immune regulation changes. Our observations, such as increased IL13, decreasing Fas, and Dickkopf proteins, also indicate possible metabolic protection. Antibodies seen in rheumatic fever are also found in antiphospholipid antibody syndromes.83 However, the incidence of autoimmune diseases in rheumatic heart disorders is very rare or possibly mutually exclusive by negative feedback mechanisms, at least in the clinical experience of the author.

Limitations and future perspectives

Further studies need to be performed to observe the immune changes in animals after direct streptococcus challenge and after the lysate administration. Specifically, the immune changes regulating the autoimmune disorders, cancer regulation, atherosclerotic processes, and host defense activities to viruses need to be studied in animal models.

Conclusion

Streptococcus pyogenes and its lysate has immunomodulation actions when tested with endothelial cells, which have pleiotropic functions. Further studies need to be performed to identify its potential benefits.

Conflict of interests

None

Source of funding

None

Ethical considerations

Not applicable

Author contributions

MCA conceived the idea and method, designed the study, interpreted results and wrote the paper. JW prepared the methods protocol, performed the tests, derived the results and principal component analysis.

Footnotes

The study was presented as an abstract in Synthetic Biology UK 2019.

Tables 1 to 5 shows biomarkers expression after direct streptococcus pyogenes injury on the endothelial cells.

Bibliography

  1. 1.↵
    Negi P, Sondhi S, Asotra S, Mahajan K, Mehta A. Current status of rheumatic heart disease in India. Indian Heart Journal. 2019;71(1):85–90.
    OpenUrl
  2. 2.↵
    Kar P, Geeta K, Gopinath R, Durga P. Mortality prediction in Indian cardiac surgery patients: Validation of European System for Cardiac Operative Risk Evaluation II. Indian Journal of Anaesthesia. 2017;61(2):157.
    OpenUrl
  3. 3.↵
    Srilata M, Padhy N, Padmaja D, Gopinath R. Does Parsonnet scoring model predict mortality following adult cardiac surgery in India?. Annals of Cardiac Anaesthesia. 2015;18(2):161. doi: 10.4103/0971-9784.154468
    OpenUrlCrossRef
  4. 4.↵
    Davarpasand T, Hosseinsabet A, Jalali A. Concomitant coronary artery bypass graft and aortic and mitral valve replacement for rheumatic heart disease: short- and mid-term outcomes. Interactive CardioVascular and Thoracic Surgery. 2015;21(3):322–328.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Vellingiri R, Ranganathan A, Kumaresan K. Prevalence of CAD in rheumatic heart disease: Is time to redefine the age for screening coronary angiography? IOSR journal of dental and medical sciences. Volume 17, Issue 6 Ver. 2 (June. 2018), PP 21–23.
    OpenUrl
  6. 6.↵
    Akesson P, Moritz L, Truedsson M, Christensson B, von Pawel-Rammingen U. IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection. Infect Immun. 2006;74(1):497–503. doi: 10.1128/IAI.74.1.497-503.2006.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    von Pawel-Rammingen U, Johansson BP, Björck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 2002;21(7):1607–1615. doi: 10.1093/emboj/21.7.1607.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    von Pawel-Rammingen U. Streptococcal IdeS and Its Impact on Immune Response and Inflammation. Journal of Innate Immunity. 2012;4(2):132–140.
    OpenUrl
  9. 9.↵
    Johansson B, Shannon O, Björck L. IdeS: A Bacterial Proteolytic Enzyme with Therapeutic Potential. PLoS ONE. 2008;3(2):e1692.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Stubbs M, Thomas M, Vendramin C, Sonesson E, Kjellman C, Järnum S et al. Administration of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti-ADAMTS 13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission. British Journal of Haematology. 2018;186(1):137–140.
    OpenUrl
  11. 11.↵
    Courtney H, Pownall H. The Structure and Function of Serum Opacity Factor: A Unique Streptococcal Virulence Determinant That Targets High-Density Lipoproteins. Journal of Biomedicine and Biotechnology. 2010;2010:1–16.
    OpenUrl
  12. 12.↵
    Gillard B, Rosales C, Pillai B, Lin H, Courtney H, Pownall H. Streptococcal Serum Opacity Factor Increases the Rate of Hepatocyte Uptake of Human Plasma High-Density Lipoprotein Cholesterol. Biochemistry. 2010;49(45):9866–9873.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Ramos, P., Shedlock, A. & Langefeld, C. Genetics of autoimmune diseases: insights from population genetics. J Hum Genet 60, 657–664 (2015). https://doi.org/10.1038/jhg.2015.94
    OpenUrlCrossRefPubMed
  14. 14.↵
    ReesF, DohertyM, Grainge Met al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis 2016;75:136–41.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551–8.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Zhu, M., Xu, W., Wei, C. et al. CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis. Cell Death Dis 10, 796 (2019). doi: 10.1038/s41419-019-1966-6
    OpenUrlCrossRef
  17. 17.↵
    Wittenbecher C, Ouni M, Kuxhaus O, Jähnert M, Gottmann P, Teichmann A et al. Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes. Diabetes. 2018;68(1):188–197.
    OpenUrl
  18. 18.↵
    Yau SW, Azar WJ, Sabin MA, Werther GA, Russo VC. IGFBP-2 - taking the lead in growth, metabolism and cancer. J Cell Commun Signal. 2015;9(2):125–142. doi: 10.1007/s12079-015-0261-2
    OpenUrlCrossRefPubMed
  19. 19.↵
    Noriyuki Koyama, Nobuhiro Morisaki, Yasushi Saito, and Y Sohsohida. Regulatory Effects of Platelet-derived Growth Factor-AA Homodimer on Migration of Vascular Smooth Muscle Cells. Journal of biological chemistry. Vol. 267, No. 32, Issue of November 15, pp, 22806–22812, 1992
    OpenUrlAbstract/FREE Full Text
  20. 20.
    Mamer, S.B., Chen, S., Weddell, J.C. et al. Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics. Sci Rep 7, 16439 (2017). doi.org/10.1038/s41598-017-16610-z
    OpenUrlCrossRefPubMed
  21. 21.↵
    Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–1312. doi: 10.1101/gad.1653708
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Koyner J, Shaw A, Chawla L, Hoste E, Bihorac A, Kashani K et al. Tissue Inhibitor Metalloproteinase-2 (TIMP-2)· IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI. Journal of the American Society of Nephrology. 2014;26(7):1747–1754.
    OpenUrl
  23. 23.↵
    de Dios Rosado J, Rodriguez-Sosa M. Macrophage Migration Inhibitory Factor (MIF): A Key Player in Protozoan Infections. International Journal of Biological Sciences. 2011;7(9):1239–1256.
    OpenUrl
  24. 24.↵
    Yue X, Wu L, Hu W. The regulation of leukemia inhibitory factor. Cancer Cell Microenviron. 2015;2(3):e877. doi: 10.14800/ccm.877
    OpenUrlCrossRef
  25. 25.↵
    Pećina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003;3(1):17. Published 2003 Oct 14. doi: 10.1186/1475-2867-3-17
    OpenUrlCrossRefPubMed
  26. 26.↵
    Nolan K, Thompson T. The DAN family: Modulators of TGF-β signaling and beyond. Protein Science. 2014;23(8):999–1012.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Kattamuri C, Luedeke D, Nolan K, Rankin S, Greis K, Zorn A et al. Members of the DAN Family Are BMP Antagonists That Form Highly Stable Noncovalent Dimers. Journal of Molecular Biology. 2012;424(5):313–327.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Huang H, Chen P, Yu C, Chuang C, Stone L, Hsiao W et al. Epithelial Cell Adhesion Molecule (EpCAM) Complex Proteins Promote Transcription Factor-mediated Pluripotency Reprogramming. Journal of Biological Chemistry. 2011;286(38):33520–33532.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    Fretto LJ, Snape AJ, Tomlinson JE, et al. Mechanism of Platelet-derived Growth Factor (PDGF)AA, AB, and BB Binding to alpha and Beta PDGF receptor. 1993;268(5):3625–3631.
    OpenUrl
  30. 30.↵
    Sheng J, Xu Z. Three decades of research on angiogenin: a review and perspective. Acta Biochimica et Biophysica Sinica. 2015;48(5):399–410.
    OpenUrl
  31. 31.↵
    Campanacci V, Bishop R, Blangy S, Tegoni M, Cambillau C. The membrane bound bacterial lipocalin Blc is a functional dimer with binding preference for lysophospholipids. FEBS Letters. 2006;580(20):4877–4883.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Gautam, V., D’Avanzo, C., Hebisch, M. et al. BACE1 activity regulates cell surface contactin-2 levels. Mol Neurodegeneration 9, 4 (2014) doi: 10.1186/1750-1326-9-4.
    OpenUrlCrossRefPubMed
  33. 33.
    Masuda T. Contactin-2/TAG-1, active on the front line for three decades. Cell Adhesion & Migration. 2017;11(5-6):524–531.
    OpenUrl
  34. 34.↵
    Pallante B, Giovannone S, Fang-Yu L, Zhang J, Liu N, Kang G et al. Contactin-2 Expression in the Cardiac Purkinje Fiber Network. Circulation: Arrhythmia and Electrophysiology. 2010;3(2):186–194.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402–407. doi: 10.1016/j.cyto.2008.07.017
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    Woo M, Xue K, Liu J, McBride H, Tsang B. Calpain-mediated Processing of p53-associated Parkin-like Cytoplasmic Protein (PARC) Affects Chemosensitivity of Human Ovarian Cancer Cells by Promoting p53 Subcellular Trafficking. Journal of Biological Chemistry. 2011;287(6):3963–3975.
    OpenUrl
  37. 37.
    Skaar J, Arai T, DeCaprio J. Dimerization of CUL7 and PARC Is Not Required for All CUL7 Functions and Mouse Development. Molecular and Cellular Biology. 2005;25(13):5579–5589.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Nikolaev A, Li M, Puskas N, Qin J, Gu W. Parc. Cell. 2003;112(1):29–40.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    Brown AJ, Sepuru KM, Sawant KV, Rajarathnam K. Platelet-Derived Chemokine CXCL7 Dimer Preferentially Exists in the Glycosaminoglycan-Bound Form: Implications for Neutrophil-Platelet Crosstalk. Front Immunol. 2017;8:1248. Published 2017 Oct 2. doi: 10.3389/fimmu.2017.01248
    OpenUrlCrossRefPubMed
  40. 40.
    Vu JP, Germano P, Lu Y, Pisegna J. Characterization of the orphan human (C-X-C) chemokine receptor type 7 receptor (CXCL7) on T lymphocyte cells. 2010, 4 supp1.
  41. 41.↵
    Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E et al. The CXCL7/CXCR1/2 Axis Is a Key Driver in the Growth of Clear Cell Renal Cell Carcinoma. Cancer Research. 2013;74(3):873–883.
    OpenUrl
  42. 42.↵
    Schenk BI, Petersen F, Flad HD, Brandt E. Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol. 2002; 169: 2602–2610.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    Shouval DS, Ouahed J, Biswas A, et al. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol. 2014;122:177–210. doi: 10.1016/B978-0-12-800267-4.00005-5
    OpenUrlCrossRefPubMed
  44. 44.↵
    Yoo K, Kim S, Chung J, Chang S. Association of IL10, IL10RA, and IL10RB Polymorphisms with Benign Prostate Hyperplasia in Korean Population. Journal of Korean Medical Science. 2011;26(5):659.
    OpenUrlPubMed
  45. 45.↵
    Tian Y, Mollo S, Harrington L, Zajac A. IL-10 Regulates Memory T Cell Development and the Balance between Th1 and Follicular Th Cell Responses during an Acute Viral Infection. The Journal of Immunology. 2016;197(4):1308–1321.
    OpenUrl
  46. 46.↵
    Watanabe K, Jose P, Rankin S. Eotaxin-2 Generation Is Differentially Regulated by Lipopolysaccharide and IL-4 in Monocytes and Macrophages. The Journal of Immunology. 2002;168(4):1911–1918.
    OpenUrl
  47. 47.↵
    Jin Y, Cheng X, Lu J, Li X. Exogenous BMP-7 Facilitates the Recovery of Cardiac Function after Acute Myocardial Infarction through Counteracting TGF-β1 Signaling Pathway. The Tohoku Journal of Experimental Medicine. 2018;244(1):1–6.
    OpenUrl
  48. 48.↵
    Ghosh M, Shen Z, Fahey J, Cu-Uvin S, Mayer K, Wira C. Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology. 2010;129(2):207–219.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    Misra P, Lebeche D, Ly H, Schwarzkopf M, Diaz G, Hajjar R et al. Quantitation of CXCR4 Expression in Myocardial Infarction Using 99mTc-Labeled SDF-1. Journal of Nuclear Medicine. 2008;49(6):963–969.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    Erdag G, Medalie D, Rakhorst H, Krueger G, Morgan J. FGF-7 Expression Enhances the Performance of Bioengineered Skin. Molecular Therapy. 2004;10(1):76–85.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    Wang W, Soto H, Oldham E, Buchanan M, Homey B, Catron D et al. Identification of a Novel Chemokine (CCL28), which Binds CCR10 (GPR2). Journal of Biological Chemistry. 2000;275(29):22313–22323.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    Zapata J, Perez-Chacon G, Carr-Baena P, Martinez-Forero I, Azpilikueta A, Otano I et al. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. Frontiers in Immunology. 2018;9.
  53. 53.↵
    Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 2014;47(3):122–129. doi: 10.5483/bmbrep.2014.47.3.283
    OpenUrlCrossRef
  54. 54.↵
    Kong DH, Kim YK, Kim MR, Jang JH, Lee S. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. Int J Mol Sci. 2018;19(4):1057. Published 2018 Apr 2. doi: 10.3390/ijms19041057.
    OpenUrlCrossRef
  55. 55.↵
    Kim, T., Park, C., Na, H. et al. Ig-like domain 6 of VCAM-1 is a potential therapeutic target in TNFα-induced angiogenesis. Exp Mol Med 49, e294 (2017). https://doi.org/10.1038/emm.2016.147
    OpenUrl
  56. 56.↵
    Richards, D.M., Marschall, V., Billian-Frey, K. et al. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality. j. immunotherapy cancer 7, 191 (2019). https://doi.org/10.1186/s40425-019-0671-4
    OpenUrl
  57. 57.↵
    Lübbers J, Rodríguez E, van Kooyk Y. Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions. Frontiers in Immunology. 2018;9.
  58. 58.↵
    Witmer A, van Blijswijk B, Dai J, Hofman P, Partanen T, Vrensen G et al. VEGFR-3 in adult angiogenesis. The Journal of Pathology. 2001;195(4):490–497.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    Duffen J, Zhang M, Masek-Hammerman K, Nunez A, Brennan A, Jones J et al. Modulation of the IL-33/IL-13 Axis in Obesity by IL-13Rα2. The Journal of Immunology. 2018;200(4):1347–1359.
    OpenUrl
  60. 60.↵
    Jeff Porter Sharman, Jerome H. Goldschmidt, John M. Burke, Beth A. Hellerstedt, Kristi McIntyre, Christopher A. Yasenchak, Thomas E. Boyd, Robert L. Ruxer, Dipti Patel-Donnelly, Fadi S. Braiteh, Andres Forero-Torres, Michael A. Savin, Tina Marie Albertson, and McKesson Specialty Health/US Oncology Research, CD 30 expresssion in non lymphomatous malignancies. Journal of Clinical Oncology 2012 30:15_suppl, 3069–3069
    OpenUrl
  61. 61.↵
    Lebrin F, Deckers M, Bertolino P, Tendijke P. TGF-Beta receptor function in the endothelium. Cardiovascular Research. 2005;65(3):599–608.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    Hou T, Tieu BC, Ray S, et al. Roles of IL-6-gp130 Signaling in Vascular Inflammation. Curr Cardiol Rev. 2008;4(3):179–192. doi: 10.2174/157340308785160570
    OpenUrlCrossRefPubMed
  63. 63.↵
    Sánchez-Zamora Y, Rodriguez-Sosa M. The Role of MIF in Type 1 and Type 2 Diabetes Mellitus. Journal of Diabetes Research. 2014;2014:1–6.
    OpenUrl
  64. 64.↵
    Yamada A, Arakaki R, Saito M, Kudo Y, Ishimaru N. Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Frontiers in Immunology. 2017;8:408. doi: 10.3389/fimmu.2017.00403
    OpenUrlCrossRef
  65. 65.↵
    Sun J. Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells. Journal of Signal Transduction. 2010;2010:1–7. doi: 10.1155/2010/98512.
    OpenUrlCrossRef
  66. 66.↵
    Adda Grimberg, Carrie M Coleman, Zonggao Shi, Timothy F Burns, Timothy MacLachlan, Wenge Wang & Wafik S. El-Deiry (2006) Insulin-like growth factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling, Cancer Biology & Therapy, 5:10, 1408–1414. doi: 10.4161/cbt.5.10.3455.
    OpenUrlCrossRef
  67. 67.↵
    Rose N. Critical Cytokine Pathways to Cardiac Inflammation. Journal of Interferon & Cytokine Research. 2011;31(10):705–710.
    OpenUrl
  68. 68.↵
    IL-13Rα2, a Decoy Receptor for IL-13 Acts As an Inhibitor of IL-4-dependent Signal Transduction in Glioblastoma Cells. Cancer Res February 15 2002;62) (4): 1103–1109.
    OpenUrl
  69. 69.↵
    Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25(57):7469–7481.
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.↵
    Medler J, Wajant H. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. Expert Opinion on Therapeutic Targets. 2019;23(4):295–307.
    OpenUrl
  71. 71.↵
    Wei Q, Wang Y, Liu H, Yang J, Yang C, Liu M et al. The expression and role of activin A and follistatin in heart failure rats after myocardial infarction. International Journal of Cardiology. 2013;168(3):2994–2997.
    OpenUrl
  72. 72.↵
    Mehta V, Besner G. Heparin-Binding Epidermal Growth Factor-Like Growth Factor Inhibits Cytokine-Induced NF-κB Activation and Nitric Oxide Production via Activation of the Phosphatidylinositol 3-Kinase Pathway. The Journal of Immunology. 2005;175(3):1911–1918.
    OpenUrl
  73. 73.↵
    Mathias L. Heltberg, Sandeep Krishna, Mogens H. Jensen. On chaotic dynamics in transcription factors and the associated effects in differential gene regulation. Nature Communications, 2019; 10 (1). doi: 10.1038/s41467-018-07932-1.
    OpenUrlCrossRef
  74. 74.↵
    S Sivaprakasam, EM Shahverdiev, PS Spencer, KA Shore. Experimental demonstration of anticipating synchronisation in chaotic semiconductor lasers with optical feedback. Physics review letters. 2001; 87(15):154101.
    OpenUrl
  75. 75.↵
    S Sivaprakasam, KA Shore. Demonstration of optical synchronization of chaotic external-cavity laser diodes. Optics letters. 1999; 24 (7): 466–468.
    OpenUrlPubMed
  76. 76.↵
    Ichinohe T, Pang I, Kumamoto Y, Peaper D, Ho J, Murray T et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proceedings of the National Academy of Sciences. 2011;108(13):5354–5359.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    Chalmers C, Khemlani A, Sohn C, Loh J, Tsai C, Proft T. Streptococcus pyogenes nuclease A (SpnA) mediated virulence does not exclusively depend on nuclease activity. Journal of Microbiology, Immunology and Infection. 2020;53(1):42–48.
    OpenUrl
  78. 78.↵
    Shi Z, Gewirtz AT. Together Forever: Bacterial-Viral Interactions in Infection and Immunity. Viruses. 2018;10(3):122. doi: 10.3390/v10030122.
    OpenUrlCrossRef
  79. 79.↵
    Darwin, C. (1845). Journal of researches into the natural history and geology of the countries visited during the voyage of the H.M.S. Beagle round the world, under the command of Captain Fitz. Roy, R.N. London: John Murray.
  80. 80.↵
    Okada H, Kuhn C, Feillet H, Bach JF. The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update. Clin Exp Immunol. 2010;160(1):1–9. doi: 10.1111/j.1365-2249.2010.04139.x
    OpenUrlCrossRefPubMedWeb of Science
  81. 81.↵
    Steincrohn P. The blood sugar and cardiac involvement in rheumatic fever. Journal of the American Medical Association. 1938;111(20):1837.
    OpenUrlCrossRef
  82. 82.↵
    Barach J. The incidence of rheumatic heart disease among diabetic patients. American Heart Journal. 1926;2(2):196–201.
    OpenUrlCrossRefWeb of Science
  83. 83.↵
    Blank M, Krause I, Magrini L, Spina G, Kalil J, Jacobsen S et al. Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Rheumatology. 2006;45(7):833–841.
    OpenUrlCrossRefPubMedWeb of Science
Back to top
Posted May 15, 2020.
Download PDF
Email
A Novel Method of Immunomodulation of Endothelial cells Using Streptococcus Pyogenes and its Lysate
Mark Christopher Arokiaraj, Jarad Wilson
bioRxiv 2020.05.13.082180; doi: https://doi.org/10.1101/2020.05.13.082180
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area